Poteligeo Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The poteligeo market research report is one of a series of new reports that provides poteligeo market statistics, including the poteligeo industry global market size, regional shares, competitors with the poteligeo market share, detailed poteligeo market segments, market trends, and opportunities, and any further data you may need to thrive in the poteligeo industry. This poteligeo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing adoption of phototherapy, a shift towards immunotherapies, improvements in healthcare infrastructure and oncology care, a focus on long-term safety and efficacy data, and a shift toward targeted therapies. Major trends in the forecast period include combination therapies, personalized medicine, technological advancements in drug delivery, telemedicine integration, and clinical trial advancements.

The rising prevalence of lymphoma is expected to drive the growth of the Poteligeo market. Lymphoma is a cancer that begins in the lymphatic system, primarily affecting the lymph nodes, spleen, and bone marrow. The increase in lymphoma cases is linked to factors such as an aging population, higher exposure to environmental risk factors, and advancements in diagnostic technologies. Poteligeo (mogamulizumab) treats lymphoma by targeting and inhibiting the CCR4 receptor on cancerous T-cells, which reduces tumor growth and enhances the immune system's response to cancer cells. For example, in 2023, the American Cancer Society reported an increase in new lymphoma cases, rising from 89,010 in 2022 to 89,380 in 2023. As a result, the growing prevalence of lymphoma is contributing to the expansion of the Poteligeo market.

Securing regulatory approvals is a key trend in the Poteligeo market to solidify its position. These approvals ensure that Poteligeo is safe, effective, and available for patients with cutaneous T-cell lymphoma, thereby broadening treatment options for rare diseases. For instance, in June 2022, Kyowa Kirin Co., Ltd., a pharmaceutical company based in Japan, received Health Canada authorization for Poteligeo (mogamulizumab for injection), a monoclonal antibody used to treat adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval was a significant achievement for the company, as Poteligeo targets CCR4-positive malignant T-cells commonly found in these forms of cutaneous T-cell lymphoma.

In October 2022, Swixx BioPharma AG, a pharmaceutical company based in Switzerland, partnered with Kyowa Kirin Holdings B.V. to enhance the accessibility of CRYSViTA and Poteligeo in Poland. The focus of this partnership is on rare diseases such as X-linked hypophosphatemia and cutaneous T-cell lymphomas, aiming to improve treatment options for patients with limited alternatives. Kyowa Kirin Holdings B.V., a Japan-based pharmaceutical company, specializes in providing Poteligeo.

The key company operating in the poteligeo market is Kyowa Kirin Co. Ltd.

North America was the largest region in the poteligeo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in poteligeo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the poteligeo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Poteligeo is a monoclonal antibody used to treat certain cancers, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). It works by targeting and inhibiting the CCR4 receptor found on the surface of cancerous T-cells in these cancers. By binding to CCR4, it helps reduce the proliferation of malignant cells and may lead to their destruction.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Poteligeo include mycosis fungoides, Sezary syndrome, and peripheral T-cell lymphoma (PTCL). Mycosis fungoides is a rare form of cutaneous T-cell lymphoma, characterized by abnormal T-cell growth in the skin, resulting in lesions. Poteligeo is distributed through various channels such as direct sales by pharmaceutical companies, wholesale distributors, and retail pharmacies. It is used by various end users, including hospitals, oncology clinics, and home healthcare providers.

The poteligeo market consists of sales of mogamulizumab injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.